Clinical Trials for Gallbladder Cancer

Paid Clinical Trials and Focus Groups by Category

Find Paid Clinical Trials

Find Paid Clinical Trials All Categories ... Medical Conditions » ... Cancers » ... Gallbladder Cancer


  • Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

    Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer
    Interventions:   Drug: erlotinib hydrochloride;   Drug: sorafenib tosylate
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2010
  • Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

    Conditions:   Anal Cancer;   Carcinoma of the Appendix;   Colorectal Cancer;   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Gastric Cancer;   Gastrointestinal Carcinoid Tumor;   Liver Cancer;   Nausea and Vomiting;   Pancreatic Cancer;   Peritoneal Cavity Cancer;   Small Intestine Cancer
    Interventions:   Drug: palonosetron hydrochloride;   Other: placebo
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2010
  • OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

    Condition:   Cancer
    Interventions:   Genetic: protein expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: biopsy
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • Capecitabine, Gemcitabine, and Radiation Therapy in Treating Patients With Cholangiocarcinoma of the Gallbladder or Bile Duct

    Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer
    Interventions:   Drug: capecitabine;   Drug: gemcitabine hydrochloride;   Procedure: adjuvant therapy;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2010
  • Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

    Condition:   Cancer
    Interventions:   Drug: fentanyl sublingual spray;   Other: questionnaire administration
    Sponsor:   Insys Therapeutics Inc
    Recruiting - verified October 2008
  • Identification of Key Blood Molecular Markers for Immunotherapy

    Conditions:   Carcinomas (Including Squamous Cell and Adenocarcinoma);   Anal Cancer;   Bile Duct Cancer (Cholangiocarcinoma);   Bladder (Urothelial, Transitional Cell) Cancer;   Blood and Marrow Transplant (BMT);   Bone Cancer;   Brain (Nervous System) Cancers;   Breast Cancer;   Colon/Rectal Cancer;   Endocrine Cancer;   Esophageal Cancer;   Eye Cancer;   Gall Bladder Cancer;   Gastric (Stomach) Cancer;   Gastro-Esophageal(GE) Junction Cancer;   Gastrointestinal Stromal Tumor (GIST);   Gynecologic Cancers;   Head and Neck Cancers;   Hepatobiliary Cancers;   Kidney (Renal Cell) Cancer;   Leukemia;   Lung Cancer;   Lymphoma: Hodgkin;   Lymphomas: Non-Hodgkin;   Mesothelioma;   Multiple Myeloma;   Myelodysplastic Syndromes (MDS);   Myeloproliferative Disorders (MPD);   Neuroendocrine Tumors;   Pancreatic Cancer;   Prostate Cancer;   Skin Cancer;   Soft Tissue Sarcoma;   Testicular Cancer;   Thymus Cancer;   Thyroid Cancer
    Intervention:   Procedure: phlebotomy
    Sponsor:   Stanford University
    Recruiting - verified August 2010
  • Bevacizumab and Erlotinib in Treating Patients With Metastatic or Unresectable Biliary Tumors

    Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer
    Interventions:   Biological: bevacizumab;   Drug: erlotinib hydrochloride;   Genetic: molecular diagnostic method;   Genetic: mutation analysis;   Genetic: protein expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Active, not recruiting - verified January 2009
  • Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

    Conditions:   Carcinomas (Including Squamous Cell and Adenocarcinoma);   Anal Cancer;   Bile Duct Cancer (Cholangiocarcinoma);   Bladder (Urothelial, Transitional Cell) Cancer;   Blood and Marrow Transplant (BMT);   Bone Cancer;   Brain (Nervous System) Cancers;   Breast Cancer;   Colon/Rectal Cancer;   Endocrine Cancer;   Esophageal Cancer;   Eye Cancer;   Gall Bladder Cancer;   Gastric (Stomach) Cancer;   Gastro-Esophageal(GE) Junction Cancer;   Gastrointestinal Stromal Tumor (GIST);   Gynecologic Cancers;   Head and Neck Cancers;   Hepatobiliary Cancers;   Kidney (Renal Cell) Cancer;   Leukemia;   Lung Cancer;   Lymphoma: Hodgkin;   Lymphomas: Non-Hodgkin;   Mesothelioma;   Multiple Myeloma;   Myeloproliferative Disorders (MPD);   Myelodysplastic Syndromes (MDS);   Neuroendocrine Tumors;   Pancreatic Cancer;   Prostate Cancer;   Skin Cancer;   Soft Tissue Sarcoma;   Testicular Cancer;   Thymus Cancer;   Thyroid Cancer
    Intervention:   Procedure: blood draw
    Sponsor:   Stanford University
    Recruiting - verified August 2010
  • Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

    Condition:   Cancer
    Interventions:   Drug: isolated perfusion;   Drug: melphalan
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting - verified July 2009
  • Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions

    Condition:   Cancer
    Intervention:   Biological: recombinant adenovirus-hIFN-beta
    Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   National Cancer Institute (NCI)
    Active, not recruiting - verified December 2005

Main Menu
Clinical Trial Locations
Clinical Trial Categories
Sponsors/Recruiting